# US 2026/0273032 A1 · Vaccination against the amyloid-beta 40 peptide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0273032 A1
- Document ID: US20260273032A1
- Status: Published application
- Kind: A1
- Application number: 19/580,953
- Filed: 2024-10-21
- Published: 2026-09-17
- Earliest claimed: 2023-10-23
- Assignees: Araclon Biotech, S.L.
- Applicants: Araclon Biotech, S.L.
- Inventors: Jose Manuel Sarasa Barrio; Jose Vicente Terencio Alemany; Jorge Loscos Aranda; Maria Rafaela Pascual Lucas; Jesus Luis Canudas Becana; Maria Montanes Bellosta; Ana Maria Lacosta Lopez-Alda
- Web page: https://patentgrep.com/patent/US20260273032A1

## CPC

- A61K 39/0007: {Nervous system antigens; Prions}
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/575: {humoral response}
- A61K 2039/6081: {Albumin; Keyhole limpet haemocyanin [KLH]}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention refers to a vaccine composition comprising amyloid beta 33-40 (Aβ33-40) peptide with an additional cysteine in the N-terminal end (CysAβ33-40) conjugated with the carrier protein keyhole limpet hemocyanin (KLH) using as the crosslinking agent the maleimidobutiric acid N-hydroxysuccinimide ester (SM) and aluminium hydroxide gel as adjuvant for the treatment and/or prevention of cerebral amyloid angiopathy (CAA), the method comprising administering a therapeutically effective amount of said vaccine composition comprising to a patient in need thereof.

## Claims

### Claim 1

A vaccine composition for use in the prevention and/or treatment of cerebral amyloid angiopathy (CAA), said vaccine composition comprising an amyloid beta 33-40 (Aβ33-40) peptide with an additional cysteine on the N-terminal end conjugated with the carrier protein keyhole limpet hemocyanin (KLH), using as the crosslinking agent the maleimidobutiric acid N-hydroxysuccinimide ester (SM) and an aluminum hydroxide gel.

### Claim 2 (depends on 1)

Composition for use, according to claim 1, wherein the aluminum hydroxide gel is Al(OH)3.

### Claim 3 (depends on 1, 2)

Composition for use, according to any of claim 1 or 2, wherein said the vaccine composition comprises the CysAβ33-40 peptide at a concentration between 50 μg/ml and 500 μg/ml.

### Claim 4 (depends on 3)

Composition for use, according to claim 3, wherein the CysAβ33-40 peptide is at a concentration of 200 μg/ml.

### Claim 5

Composition for use, according to any of the preceding claims, wherein said vaccine composition is administered by an administration route selected from the group consisting of intravenous, subcutaneous, intramuscular, intradermal, intraperitoneal, intrapulmonary, intranasal, oral, rectal, and combinations thereof.

### Claim 6 (depends on 5)

Composition for use, according to claim 5, wherein said vaccine composition is administered subcutaneously.

### Claim 7

Composition for use, according to any of the preceding claims, wherein said vaccine composition is administered at multiple intervals as part of a multiple-dosage regimen.

### Claim 8 (depends on 7)

Composition for use, according to claim 7, wherein said multiple dosing regimen comprises multiple portion doses administered on weeks 0, 4, 8, 12 and 16.

### Claim 9 (depends on 8)

Composition for use, according to claim 8, wherein said multiple dosing regimen further comprises a booster administered on week 42.

### Claim 10 (depends on 9)

Composition for use, according to claim 9, wherein said multiple dosing regimen further comprises a booster administered on week 58.

### Claim 11

Composition for use, according to any of the preceding claims, wherein the vaccine composition is administered at individual doses of about 0.5 ml to about 2 ml per interval as part of a multiple-dosage regimen.

### Claim 12

Composition for use, according to any of the preceding claims, wherein supplementary active compounds and molecules are used in combination with said vaccine composition.

### Claim 13 (depends on 12)

Composition for use, according to claim 12, wherein said supplementary active compounds or molecules are plasma-based proteins.

### Claim 14 (depends on 13)

Composition for use, according to claim 13, wherein said plasma-based proteins include those purified from a suitable plasma source, and are selected from the group consisting of albumin, alpha-1 antitrypsin/alpha-1 proteinase inhibitor, antithrombin, polyclonal immunoglobulins such as IgG, IgA, and combinations thereof, polyspecific immunoglobulins such as IgM, C1 esterase inhibitor, transthyretin, and combinations thereof.

### Claim 15 (depends on 12, 13, 14)

Composition for use, according to claims 12 to 14, wherein said supplementary active compounds or molecules are neurogenic/neurotrophic compounds and molecules.

### Claim 16 (depends on 15)

Composition for use, according to claim 15, wherein said neurogenic and/or neurotrophic compounds and molecules are selected from the group consisting of brain-derived neurotrophic factor, glial cell line-derived neurotrophic factor, cilliary neurotrophic factor-1, amino acids 1-38 of pituitary adenylate cyclase-activating polypeptide, Y-27632 pharmaceutically and acceptable salts thereof [trans-4-[(1R)-1-Aminoethyl]-N-4-pyridinylcyclohexanecarboxamide], fasudil and pharmaceutically acceptable salts thereof [hexahydro-1-(5-isoquinolinyl-sulfonyl)-1H-1,4-diazepine], and combinations thereof.

### Claim 17

Composition for use, according to any of the preceding claims, wherein said vaccine composition constitutes at least 20% by weight of the total protein content utilised in the therapeutic method.

### Claim 18

Composition for use according to any of the preceding claims wherein said vaccine composition is used in combination with one or more vaccines for the prevention and/or treatment of CAA or other associated neurological disorders, in particular Alzheimer's Disease.
